Having years of experience, I have witnessed the great impact of metabolic disorders like type 2 diabetes mellitus and obesity on patients’ lives. I would see patients struggling with weight, blood sugar and increasing health complications that come with metabolic disorder.
15 years ago, managing medications for metabolic diseases managed one aspect of the disease, either lowering blood sugar or helping with weight.
But never truly addressed the underlying metabolic dysfunction. Their conditions were controlled marginally but were far from resolved. Then came the dual and triple agonists, which showed promising results for treatment. One such dual agonist is Tirzepatide.
Read the full article here: https://www.thelondonobesityclinic.co.in/tirzepatide-and-dual-triple-agonists-the-next-generation-of-metabolic-drugs/
